Heterozygous Deficiency of PHD2 Restores Tumor Oxygenation and Inhibits Metastasis via Endothelial Normalization

A key function of blood vessels, to supply oxygen, is impaired in tumors because of abnormalities in their endothelial lining. PHD proteins serve as oxygen sensors and may regulate oxygen delivery. We therefore studied the role of endothelial PHD2 in vessel shaping by implanting tumors in PHD2(+/-) mice. Haplodeficiency of PHD2 did not affect tumor vessel density or lumen size, but normalized the endothelial lining and vessel maturation. This resulted in improved tumor perfusion and oxygenation and inhibited tumor cell invasion, intravasation, and metastasis. Haplodeficiency of PHD2 redirected the specification of endothelial tip cells to a more quiescent cell type, lacking filopodia and arrayed in a phalanx formation. This transition relied on HIF-driven upregulation of (soluble) VEGFR-1 and VE-cadherin. Thus, decreased activity of an oxygen sensor in hypoxic conditions prompts endothelial cells to readjust their shape and phenotype to restore oxygen supply. Inhibition of PHD2 may offer alternative therapeutic opportunities for anticancer therapy.

[1]  Patrick D. Sutphin,et al.  Coordinate Regulation of the Oxygen-Dependent Degradation Domains of Hypoxia-Inducible Factor 1α , 2005, Molecular and Cellular Biology.

[2]  Holger Gerhardt,et al.  Pericytes: gatekeepers in tumour cell metastasis? , 2008, Journal of Molecular Medicine.

[3]  A. Harris,et al.  Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. , 2003, Cancer research.

[4]  Na Zhang,et al.  Deletion of Vascular Endothelial Growth Factor in myeloid cells accelerates tumorigenesis , 2008, Nature.

[5]  F. Orsenigo,et al.  Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5 , 2008, Nature Cell Biology.

[6]  Gavin Thurston,et al.  The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth , 2007, Nature Reviews Cancer.

[7]  A. Luttun,et al.  Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 , 2002, Nature Medicine.

[8]  S. Egginton,et al.  Inhibition of endogenous HIF inactivation induces angiogenesis in ischaemic skeletal muscles of mice , 2004, The Journal of physiology.

[9]  R. Gerszten,et al.  Role of endothelial nitric oxide synthase in endothelial activation: insights from eNOS knockout endothelial cells. , 2004, American journal of physiology. Cell physiology.

[10]  Victoria L. Bautch,et al.  The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching , 2008, The Journal of cell biology.

[11]  Michael I. Wilson,et al.  C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation , 2001, Cell.

[12]  J. Peng,et al.  The transcription factor EPAS-1/hypoxia-inducible factor 2alpha plays an important role in vascular remodeling. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[13]  K. Alitalo,et al.  VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia , 2003, The Journal of cell biology.

[14]  D. McDonald,et al.  Cellular abnormalities of blood vessels as targets in cancer. , 2005, Current opinion in genetics & development.

[15]  M. Giacca,et al.  Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels , 2007, Cell.

[16]  P. Bedossa,et al.  Overexpression of the Oxygen Sensors PHD-1, PHD-2, PHD-3, and FIH Is Associated with Tumor Aggressiveness in Pancreatic Endocrine Tumors , 2008, Clinical Cancer Research.

[17]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[18]  N. Asai,et al.  Regulation of VEGF-mediated angiogenesis by the Akt/PKB substrate Girdin , 2008, Nature Cell Biology.

[19]  R. Sainson,et al.  Active involvement of Robo1 and Robo4 in filopodia formation and endothelial cell motility mediated via WASP and other actin nucleation‐promoting factors , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  K. Takeda,et al.  Essential Role for Prolyl Hydroxylase Domain Protein 2 in Oxygen Homeostasis of the Adult Vascular System , 2007, Circulation.

[21]  Soumen Paul,et al.  Activation of the VEGFR1 Chromatin Domain , 2008, Journal of Biological Chemistry.

[22]  K. Takeda,et al.  Prolyl Hydroxylase Domain 2 Protein Suppresses Hypoxia-Induced Endothelial Cell Proliferation , 2007, Hypertension.

[23]  W. Kaelin,et al.  Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. , 2008, Blood.

[24]  Charles H. Graham,et al.  Hypoxia-driven selection of the metastatic phenotype , 2007, Cancer and Metastasis Reviews.

[25]  L. Naldini,et al.  Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. , 2004, Cancer cell.

[26]  Jianhua Huang,et al.  A Role for VEGF as a Negative Regulator of Pericyte Function and Vessel Maturation , 2008, Nature.

[27]  W. Kaelin,et al.  Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. , 2008, Molecular cell.

[28]  K. Takeda,et al.  Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. , 2008, Blood.

[29]  P. Bénit,et al.  Targeted Deletion of AIF Decreases Mitochondrial Oxidative Phosphorylation and Protects from Obesity and Diabetes , 2007, Cell.

[30]  M. Corada,et al.  Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, β-catenin, and the phosphatase DEP-1/CD148 , 2003, The Journal of cell biology.

[31]  Lei Xu,et al.  Perivascular nitric oxide gradients normalize tumor vasculature , 2008, Nature Medicine.

[32]  Lei Xu,et al.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.

[33]  M. Kiupel,et al.  The Biphasic Role of the Hypoxia-Inducible Factor Prolyl-4-Hydroxylase, PHD2, in Modulating Tumor-Forming Potential , 2008, Molecular Cancer Research.

[34]  Fabian Kiessling,et al.  Vascular normalization in Rgs5-deficient tumours promotes immune destruction , 2008, Nature.

[35]  V. Vasioukhin.  Faculty Opinions recommendation of Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, beta-catenin, and the phosphatase DEP-1/CD148. , 2003 .

[36]  Joseph B. Kearney,et al.  The VEGF receptor flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis. , 2004, Blood.

[37]  P. Carmeliet,et al.  Targeted Deficiency or Cytosolic Truncation of the VE-cadherin Gene in Mice Impairs VEGF-Mediated Endothelial Survival and Angiogenesis , 1999, Cell.

[38]  M. Celeste Simon,et al.  Multiple Factors Affecting Cellular Redox Status and Energy Metabolism Modulate Hypoxia-Inducible Factor Prolyl Hydroxylase Activity In Vivo and In Vitro , 2006, Molecular and Cellular Biology.

[39]  Y. Fujii‐Kuriyama,et al.  Hypoxia-inducible Transcription Factor-2α in Endothelial Cells Regulates Tumor Neovascularization through Activation of Ephrin A1* , 2008, Journal of Biological Chemistry.

[40]  L. Claesson‐Welsh,et al.  Platelet-derived growth factor receptor-beta promotes early endothelial cell differentiation. , 2006, Blood.

[41]  C. Wykoff,et al.  Genetic Analysis of the Role of the Asparaginyl Hydroxylase Factor Inhibiting Hypoxia-inducible Factor (HIF) in Regulating HIF Transcriptional Target Genes* , 2004, Journal of Biological Chemistry.

[42]  F. Soncin,et al.  HIF-2α specifically activates the VE-cadherin promoter independently of hypoxia and in synergy with Ets-1 through two essential ETS-binding sites , 2007, Oncogene.

[43]  D. Nolan,et al.  Endothelial Progenitor Cells Control the Angiogenic Switch in Mouse Lung Metastasis , 2008, Science.

[44]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[45]  Robert A. Harris,et al.  Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism , 2008, Nature Genetics.

[46]  Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. , 2008, Nature medicine.

[47]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[48]  Holger Gerhardt,et al.  Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis , 2007, Nature.

[49]  K. Miyazono,et al.  Enhancement of angiogenesis through stabilization of hypoxia-inducible factor-1 by silencing prolyl hydroxylase domain-2 gene. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[50]  Y. Fujii‐Kuriyama,et al.  A Novel Class of Prolyl Hydroxylase Inhibitors Induces Angiogenesis and Exerts Organ Protection Against Ischemia , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[51]  P. Jaakkola,et al.  Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases. , 2004, The Biochemical journal.